ProfileJobs

Nektar Therapeutics

Healthbiotechdrug developmentoncologypharma

Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

Revenue(Q1, 2017)
$24.7 M
Market capitalization(2017-08-17)
$2.9 B
Company Growth (employees)
Type
Public
HQ
San Francisco, US
Founded
1990
Size (employees)
468 (est)
Website
nektar.com
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US

Key People at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian Thomsen

Jillian Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy Riley

Timothy Riley

Senior Vice President, Technology Assessment and Quality Assurance

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Huntsville, US
1112 Church Street

Nektar Therapeutics Data and Metrics

Nektar Therapeutics Financial Metrics

Nektar Therapeutics's revenue was reported to be $24.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

24.7 m

Gross profit (Q1, 2017)

18.6 m

Gross profit margin (Q1, 2017), %

75%

Net income (Q1, 2017)

(63.9 m)

EBIT (Q1, 2017)

(54.4 m)

Market capitalization (17-Aug-2017)

2.9 b

Cash (31-Mar-2017)

23.5 m
Nektar Therapeutics's current market capitalization is $2.9 b.
USDFY, 2013FY, 2014Y, 2015FY, 2016

Revenue

148.9 m200.7 m230.8 m165.4 m

Revenue growth, %

35%15%(28%)

Cost of goods sold

38.5 m28.5 m34.1 m30.2 m

Gross profit

110.4 m172.2 m196.7 m135.2 m

Gross profit Margin, %

74%86%85%82%

R&D expense

203.8 m

General and administrative expense

44.3 m

Operating expense total

230.5 m188.7 m260.2 m278.3 m

EBIT

(120.1 m)(16.5 m)(29.4 m)(112.9 m)

EBIT margin, %

(81%)(8%)(13%)(68%)

Interest expense

18.5 m17.9 m18.3 m22.5 m

Interest income

732 k814 k

Pre tax profit

(159.8 m)

Income tax expense

2.2 m(512 k)506 k876 k

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

28.5 m132.9 m108.8 m22.7 m60 m58.9 m32.8 m36.3 m24.7 m

Cost of goods sold

5.1 m9.2 m8.4 m10.5 m6.8 m8.9 m7.7 m7 m6.1 m

Gross profit

23.4 m123.7 m100.4 m12.1 m53.2 m50 m25.1 m29.3 m18.6 m

Gross profit Margin, %

82%93%92%54%89%85%76%81%75%

R&D expense

36.7 m34.2 m47 m45.4 m43.2 m49.3 m52.4 m52 m61.1 m

General and administrative expense

9.6 m9.1 m10.3 m10.2 m9.5 m10.2 m11 m10.3 m12 m

Operating expense total

46.3 m43.3 m57.3 m55.6 m52.8 m59.5 m63.4 m62.2 m73 m

EBIT

(22.9 m)80.3 m43 m(43.5 m)419 k(9.5 m)(38.3 m)(32.9 m)(54.4 m)

EBIT margin, %

(80%)60%40%(192%)1%(16%)(117%)(91%)(220%)

Interest expense

(4.5 m)(4.4 m)(4.2 m)(4.1 m)(4.2 m)(5.7 m)(5.6 m)(5.6 m)(5.4 m)

Interest income

132 k133 k

Pre tax profit

(32.4 m)(52.5 m)(48.5 m)(43.1 m)(63.7 m)

Income tax expense

195 k248 k213 k164 k92 k167 k127 k139 k133 k

Net Income

(32.6 m)70.6 m33.8 m(52.7 m)(8.2 m)(19.5 m)(48.6 m)(43.2 m)(63.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.1 m12.4 m55.6 m59.6 m

Inventories

13.5 m13 m11.3 m11.1 m

Current Assets

257.9 m288.2 m350.1 m426.3 m

PP&E

67 m70.4 m71.3 m65.6 m

Goodwill

76.5 m76.5 m76.5 m76.5 m

Total Assets

434.5 m441.6 m502.1 m568.9 m

Accounts Payable

9.1 m2.7 m2.4 m2.8 m

Current Liabilities

98.2 m64 m61.2 m72.2 m

Total Liabilities

480.7 m

Additional Paid-in Capital

1.6 b1.8 b1.9 b2.1 b

Retained Earnings

(1.7 b)(1.8 b)(1.9 b)(2 b)

Total Equity

(89.9 m)36.3 m6.4 m88.1 m

Financial Leverage

-4.8 x12.2 x78.1 x6.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

30.7 m32 m129.5 m20.9 m18.8 m72.5 m55.7 m63.3 m23.5 m

Accounts Receivable

3 m46.1 m2.9 m3.7 m3 m39.7 m27.8 m14.2 m1.6 m

Inventories

14.1 m11.7 m12.5 m10.1 m10.4 m11.3 m10.3 m10.8 m13 m

Current Assets

298.2 m324.1 m347.3 m302.2 m286.4 m344.8 m318.3 m282.5 m381 m

PP&E

71.1 m69.3 m69.3 m72.2 m72.5 m69.9 m67.8 m65.6 m66.6 m

Goodwill

76.5 m76.5 m76.5 m76.5 m76.5 m76.5 m76.5 m76.5 m76.5 m

Total Assets

478.1 m476.9 m499.2 m456.7 m449.2 m491.9 m463.1 m425.1 m528.5 m

Accounts Payable

7.4 m5.4 m5 m2.8 m2.3 m2.3 m2.3 m7.1 m7 m

Current Liabilities

84.4 m80.5 m75.4 m81.1 m208.1 m65.9 m79.3 m76.3 m78.5 m

Additional Paid-in Capital

1.8 b1.8 b1.8 b1.8 b1.9 b1.9 b1.9 b1.9 b2.1 b

Retained Earnings

(1.8 b)(1.7 b)(1.8 b)(1.8 b)(1.8 b)(1.9 b)(1.9 b)(2 b)(2.1 b)

Total Equity

(35.4 m)47.2 m77.3 m35.1 m39.1 m(275 k)(39.3 m)(67.9 m)44.7 m

Financial Leverage

-13.5 x10.1 x6.5 x13 x11.5 x-1788.7 x-11.8 x-6.3 x11.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)

Depreciation and Amortization

14.3 m12.9 m12.9 m15.4 m

Accounts Receivable

3.6 m(1.4 m)(16 m)4.3 m

Inventories

4.8 m500 k1.6 m237 k

Accounts Payable

6.2 m(6.4 m)(412 k)518 k

Cash From Operating Activities

(38.5 m)(142 m)(73.1 m)(117 m)

Purchases of PP&E

(4.1 m)(10 m)(11.2 m)(6.4 m)

Cash From Investing Activities

49.9 m(37.6 m)(14.3 m)(82.4 m)

Cash From Financing Activities

2.2 m153 m130.8 m203.6 m

Interest Paid

17.6 m17.4 m20.2 m20.6 m

Income Taxes Paid

1 m964 k860 k757 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(32.6 m)70.6 m33.8 m(52.7 m)(8.2 m)(19.5 m)(48.6 m)(43.2 m)(63.9 m)

Depreciation and Amortization

3 m

Accounts Receivable

3 m46.1 m722 k3.7 m3 m39.7 m27.8 m14.2 m1.6 m

Inventories

14.1 m11.7 m441 k10.1 m10.4 m11.3 m10.3 m10.8 m13 m

Accounts Payable

7.4 m5.4 m2.2 m2.8 m2.3 m2.3 m2.3 m7.1 m7 m

Cash From Operating Activities

63.3 m

Purchases of PP&E

(1.1 m)

Cash From Investing Activities

53.2 m

Cash From Financing Activities

587 k

Interest Paid

7.9 m
USDY, 2017

Revenue/Employee

52.8 k

Financial Leverage

11.8 x

Nektar Therapeutics Market Value History

Market Position of Nektar Therapeutics

Competitors

TESARO
Health - Public
Karyopharm Therapeutics
Health - Public
Merrimack Pharmaceuticals
Health - Public
Infinity Pharmaceuticals
Health - Public
Compare competitors

Traffic Overview of Nektar Therapeutics

Nektar Therapeutics Online and Social Media Presence

Nektar Therapeutics Company Life and Culture

You may also be interested in